Archimed
Sponsors drive record take-private activity as deployment pressure mounts
Discounted small- and mid-cap take privates expected to feed 2 pipelines amid M&A and IPO slowdown
Archimed closes MED II on EUR 3.5bn
Healthcare-focused GP took 17 months to raise its second mid-cap fund, which has already deployed almost EUR 1bn
ArchiMed reaps 4x on Bomi sale to UPS
Deal is first full exit from specialist healthcare investor's maiden mid-market fund
ArchiMed exits Eurolyser to trade for 6x return
The exit is the first for ArchiMed MED II fund, which post-deal will own ten other companies
Specialist healthcare funds on track for another record year
GPs raised EUR 4.4bn with swelling need for healthcare investment but could face challenges in keeping a disciplined deployment
ArchiMed circulates teasers for Bomi auction
Healthcare-focused logistics company is being marketed off EUR 40m EBITDA
ArchiMed nets 4x return on Fytexia exit
GP has sold Fytexia to trade Associated British Foods
ArchiMed launches second mid-cap fund
Med Platform II will aim to make 8-12 investments in the mid-market, and will be larger than its EUR 1bn predecessor
ArchiMed preps Bomi auction
ArchiMed launched a EUR 70m takeover bid for Bomi in March 2019
ArchiMed buys lab analysis company Carso
Selling shareholders include private equity firms EMZ Partners, Etoile ID, Unigrains, Raise and Siparex
ArchiMed buys Cardioline
Cardiology telemedicine platform is the first deal from the GP's EUR 650m MED III fund
ArchiMed's MED II fund fully invested following Cube buyout
Cube is the last platform investment for the MED II fund, which closed in 2017
ArchiMed invests in Xpress Biologics
Plasmid DNA and protein therapy developer is an investment from the GP's Med II fund
ArchiMed raises EUR 650m in less than two months
Fund is double the size of its predecessor, MED II, which is now invested in 11 companies
ArchiMed buys Stragen Pharma
GP is investing via its €1bn Med Platform I, which backs healthcare firms with EVs of at least €100m
Biotech market provides dose of optimism
In the past year, the biotech market has seen buoyant activity, reaching record levels of investments
ArchiMed chair Ribon moves to New York office
ArchiMed also makes five new hires, including the appointment of BC Partners' Justin Bateman as partner
ArchiMed-backed Bomi bolts on Deco Pharma
With this add-on, the company plans to further strengthen its presence across southern Europe
ArchiMed acquires Zyto Group
ArchiMed has acquired a majority stake in Germany-based Zyto Group, a company that develops cancer diagnostic tests and equipment.
ArchiMed's Bomi bolts on Florence Shipping
Third add-on inked by Bomi, following its acquisition of Logifarma and its purchase of ILS
GP Profile: ArchiMed
Following the close of its new €1bn fund, ArchiMed's Denis Ribon discusses the firm's fundraising experience and investment pipeline
ArchiMed closes MED Platform I on €1bn
Oversubscribed fund closes above its €800m target after a couple of years on the road
ArchiMed's Bomi bolts on Logifarma
With the GP's support, Bomi intends to pursue an intensive buy-and-build strategy
Warburg Pincus invests in ArchiMed-backed Polyplus
ArchiMed and Warburg will be equal shareholders, while the management of Polyplus will retain a minority